Blepharitis News and Research

RSS
A common disorder of the eye, blepharitis, is a condition in which there is visible inflammation in the eyelids. Bacteria causes irritation and the eyelids become red and itchy. Though it does not cause permanent damage to vision, blepharitis causes discomfort to patients. Women in their peri- and post-menopausal stage are more prone to the dysfunction of the meibomian glands.
RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Inspire reports net loss of $17.6 million for first quarter 2011

Inspire reports net loss of $17.6 million for first quarter 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire fourth quarter revenues increase 2% to $30.3 million

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Santen launches DIQUAS Ophthalmic Solution in Japan

Santen launches DIQUAS Ophthalmic Solution in Japan

Inspire third quarter net loss decreases to $7.6 million

Inspire third quarter net loss decreases to $7.6 million

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire second-quarter total revenue increases 18% to $27.3 million

Inspire second-quarter total revenue increases 18% to $27.3 million

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.